Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
13 juil. 2018 09h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information...
Capricor Therapeutics to Present at PPMD Annual Conference
28 juin 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, June 28, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics’ (NASDAQ:CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular...
Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
27 juin 2018 07h00 HE
|
Summit Therapeutics plc
Ezutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST OXFORD, United Kingdom and...
Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
29 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 29, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare disorders,...
Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
10 mai 2018 16h00 HE
|
Capricor Therapeutics, Inc.
HOPE-2 Clinical Trial is Currently Enrolling Patients Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 10, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a...
Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
03 mai 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that Linda Marbán, Ph.D., Capricor president and CEO, will provide a presentation on exosomes at...
Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
30 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test...
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
20 avr. 2018 07h00 HE
|
Summit Therapeutics plc
Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE...
Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
12 avr. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that it will be among the companies providing presentations at the Alliance for Regenerative...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress
11 avr. 2018 07h00 HE
|
Summit Therapeutics plc
Conference Call Today at 1:00pm BST / 8:00am EDT OXFORD, United Kingdom and CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) today reports its...